References
Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol. 2000;119:225–30.
Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14:1343–50.
Roujeau JC, Bricard G, Nicolas JF. Drug-induced epidermal necrolysis: important new piece to end the puzzle. J Allergy Clin Immunol. 2011;128:1277–8.
Brockow K, Romano A. Skin tests in the diagnosis of drug hypersensitivity reactions. Curr Pharm Des. 2008;14:2778–91.
Kano Y, Inaoka M, Sakuma K, Shiohara T. Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced hypersensitivity syndrome. Toxicology. 2005;209:165–7.
Kang S, Cho S, Chung JH, Hammerberg C, Fisher GJ, Voorhees JJ. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol. 2005;166:1691–9.
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–79.
Ostrov DA, Grant BJ, Pompeu YA, Sidney J, Harndahl M, Southwood S, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A. 2012;109:9959–64.
Rive CM, Bourke J, Phillips EJ. Testing for drug hypersensitivity syndromes. Clin Biochem Rev. 2013;34:15–38.
Vocanson M, Achachi A, Mutez V, Cluzel-Tailhardat M, Varlet BL, Rozières A, et al. Human T cell priming assay: depletion of peripheral blood lymphocytes in CD25(+) cells improves the in vitro detection of weak allergen-specific T cells. EXS. 2014;104:89–100.
Pichler WJ. The p-i Concept: pharmacological interaction of drugs with immune receptors. World Allergy Organ J. 2008;1:96–102.
Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88:60–8.
Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, et al.; RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133(5):1197–204.
Niihara H, Kakamu T, Fujita Y, Kaneko S, Morita E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol. 2012;39:594–601.
Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134–9.
Ushigome Y, Kano Y, Hirahara K, Shiohara T. Human herpesvirus 6 reactivation in drug-induced hypersensitivity syndrome and DRESS validation score. Am J Med. 2012;125:e9–10.
Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol. 2009;182:8071–9.
Criado PR, Criado RF, Avancini Jde M, Santi CG. Drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS): a review of current concepts. An Bras Dermatol. 2012;87:435–49.
Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol. 2013;68:721–8.
Acknowledgments
We thank all the participants in the World SCAR meeting who participated in answering the questionnaire assessing different topics regarding SCAR, including the members of the different international research groups: RegiSCAR network, Japan-SCAR, Southeast Asia-SCAR. Special gratitude to Professor Maja Mockenhaupt, Professor Jean-Claude Roujeau, Professor Alexis Sidoroff, Professor Tetsuo Shiohara, Professor Yoko Kano, Professor Werner J. Pichler, Professor Elizabeth J. Phillips, Professor Simon A. Mallal, Professor Thirumoorthy Thamotharampillai, Professor Jean-François Nicolas and congress secretary-Yen-Ling Lin.
Funding and Conflicts of Interest
No sources of funding were used to assist in the preparation of this report. The Drug Hypersensitivity Clinical and Research Center is supported by grants from Chang Gung Memorial Hospital and the Ministry of Science and Technology, Taiwan. Roni P. Dodiuk-Gad, Wen-Hung Chung, Chih-Hsun Yang, Chun-Wei Lu, Rosaline Chung-Yee Hui and Neil H. Shear have no conflicts of interest that are directly relevant to the content of this report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dodiuk-Gad, R.P., Chung, WH., Yang, CH. et al. The 8th International Congress on Cutaneous Adverse Drug Reactions, Taiwan, 2013: Focus on Severe Cutaneous Adverse Reactions. Drug Saf 37, 459–464 (2014). https://doi.org/10.1007/s40264-014-0165-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40264-014-0165-8